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Preparation of Fluorescent Microcystin Derivatives via Direct 
Arginine Labelling and their Biological Evaluation 
Verena Grundler[a], Susanne Faltermann[b], Karl Fent[b,c] and Karl Gademann*[a] 
 
Abstract: Microcystin constitutes the most prevalent toxin produced 
by cyanobacteria and poses a severe threat to livestock, humans 
and whole ecosystems. We report the preparation of a series of 
fluorescent microcystin derivatives through direct arginine labelling 
of the unprotected peptides at the guanidinium side chain. This new 
method allows for a late-stage diversification strategy of native 
peptides devoid of protecting groups under mild and operationally 
simple conditions. A series of fluorophores have been conjugated to 
microcystin-LR in good to very good yield. The fluorescent probes 
displayed comparable biological activity to unlabelled microcystin in 
both phosphatase inhibition assays and toxicity tests on the 
crustacean Thamnocephalus platyurus. In addition, we 
demonstrated that the fluorescent probes penetrated Huh7 cells. 
Whole animal imaging was performed on T. platyurus, and the 
labeled compound was mainly observed in the digestive tract. 
Introduction 
Climate change, eutrophication, and increase in agricultural and 
other activities have led to an exacerbation of cyanobacterial 
blooms in water bodies worldwide. Their impact on fisheries, 
tourism, recreational activity and the whole ecosystem is 
considered severe, as often drinking water supplies need to be 
monitored or beaches closed. This issue is further complicated 
by the fact that various toxic secondary metabolites are 
produced by cyanobacteria.[1-4] The release of these compounds 
in the context of cyanobacterial blooms poses a serious threat 
for water supply, public health and for livestock and wildlife 
worldwide.[5-7] Microcystins (MC) constitute the most abundantly-
observed toxins and over 80 different congeners of these cyclic 
non-ribosomal depsipeptides have been described. In this 
domain, microcystin-LR (MC-LR) occupies a prominent position, 
as it constitutes the most extensively studied toxin due to its 
potent LD50 value (50 µgkg-1 in rats).[8] The World Health 
Organization (WHO) has set a maximal guideline value of 1 µgL-
1 for MC-LR in drinking water, which further emphasizes its 
potency and toxicity.[9,10] In humans, this substance shows a 
hepatotoxic effect through inhibition of protein phosphatases 1 
(PP1) and 2A (PP2A) and the chronic exposure to this toxin can 
cause liver cancer.[11-13] MC-LR also causes a disruption of the 
cytoskeletal components accompanied by cell deformation 
initiated by cytokeratin hyperphosphorylation, which ends in a 
collapse of the whole liver architecture.[14] Moreover, MC-LR has 
been reported to cause DNA-damage, apoptosis, disruption in 
the cell-signalling and endoplasmic reticulum stress.[15-17] The 
known transport of MCs in the cell is mediated by the organic 
anion polypeptide transporter (OATP), e.g. in human 
hepatocytes.[18,19] In aquatic organisms, which are particularly 
vulnerable to cyanobacterial microcystins due to the increased 
levels of exposure, such toxic effects are also displayed. For 
example, in Daphnia magna, which is an important grazer of 
cyanobacteria as a food source, disturbance in the reproduction 
together with higher mortality rates and deteriorated 
development are observed.[20-24] In fish and invertebrates, the 
toxin accumulates in the tissues and leads to a number of toxic 
effects.[25,26] 
Even though microcystins have been known for decades, the 
reasons for the strong toxicity in animals are not yet fully 
understood. To gain an insight into the uptake, distribution, 
accumulation and excretion of MC-LR, biological studies using 
chemical microcystin probes are necessary. In this study, we 
have prepared fluorescently labelled MC-LR in order to monitor 
its behaviour, uptake and excretion in aquatic animals.  
First, a site suitable for chemical modification that did not impact 
the biological activity of MC had to be identified. It has been 
reported that the reactive Mdha groups bind in a Michael-type 
addition covalently to Cys 273 of the protein phosphatase 1 and 
the Adda side chain interacts with the hydrophobic cage of the 
active pocket.[27] Furthermore, inspection of the crystal structure 
of the MC-LR/PP1 complex shows that leucine and the 
carboxylate groups are also involved in enzyme binding.[28] 
Interestingly, this crystal structure reveals that the arginine side 
chain protrudes from the binding pocket suggesting that the Arg 
residue is not participating in the inhibition of the phosphatase 
and, thus, presents a promising site for modification. However, 
efficient acetylation of the arginine guanidine group proved to be 
difficult due to the high pKa value of this protonated side chain 
(pKa = 12.5). Shreder and co-workers have successfully 
introduced a fluorophore at this moiety in MC-LR with a 
compromised yield by using a two-step procedure.[29] Similar 
yields were obtained by a comparable reaction to a MC-LR-DNA 
conjugate.[30] In consideration of the limited availability of the 
toxin, improved methods are needed to modify MC-LR. We 
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recently reported a method for the late-stage modification of the 
arginine side chain in unprotected, native peptides.[31]  
In this study, we will present (1) the application of this method in 
the context of labelling microcystin with a number of 
fluorophores; (2) biological evaluation of the labelled compounds 
in a series of enzymatic, cellular, and toxicity assays in animals, 
and (3) a distribution study of the labelled microcystin derivatives 
in the ecotoxicological relevant crustacean Thamnocephalus 
platyurus. 
 
Scheme 1. Fluorescently labeled MC-LR derivatives via direct 
arginine modification 
Results and Discussion 
As already discussed, modification of the arginine residue in 
microcystin-LR should not interfere with enzyme binding, as 
suggested by inspection of the crystal structure of the 
microcystin/phosphatase complex.[28] Furthermore, 
hypervariations in the amino acid sequence at this position in 
natural occurring microcystins support the hypothesis that this 
residue is central for the inhibitory effect. To find an effective 
labelling method for MC-LR, we had to consider several 
difficulties: (a) The poor reactivity of the guanidinium group, (b) 
MC-LR contains other reactive groups like the reactive 
unsaturated Mdha residue, (c) MC-LR gets degraded under 
strong basic or acidic conditions, and (d) the availability of the 
toxin, which can only be isolated in small amounts.[32] 
Thus, different strategies for labelling this moiety had to be 
evaluated, and based on our recently published method, [31] we 
opted for the use of Barton’s base. The coupling of MC-LR was 
performed under standard conditions by dissolving the toxin in 
DMF and adding Barton’s base. After initial stirring at 40 °C and 
subsequent addition of the different, dissolved activated ester, 
the reaction was continued for eight hours. To our delight, the 
desired products functionalized with different fluorescent 
reported groups were obtained in moderate to good yields (55 % 
to 84 %). Utilizing this method, four fluorescently labelled 
derivatives were synthesized (Scheme 1).  
 
After successfully labelling MC-LR with different fluorophores, 
we investigated their photochemical properties. The maximum 
absorption of the derivatives was at 499 nm for MC-LR-(5,6-
FAM), at 425 nm for MC-LR-(Alexa-430) and at 586 for MC-LR-
(Texas-Red) (see supporting information). Furthermore, the 
maximum emission is located at 525 nm for MC-LR-(5,6-FAM), 
at 434 nm for MC-LR-(Alexa-430) and at 605 nm for 
MC-LR-(Texas-Red). With this data, we were able to select the 
right compounds for the various uptake studies, with regard to 
the overlap of the intrinsic fluorescence of the used compounds 
and biological test systems. To visualize the spectral colour of 
the different compounds, colour space chromaticity diagrams 
were recorded. MC-LR-(5,6-FAM) is located more in the 
yellowish-green range (x: 0.32 y: 0.66), whereas MC-LR-(Alexa-
430) is already in the yellow-green area (x: 0.38 y: 0.58) and  
MC-LR-(Texas-Red) is situated in the orange-yellow section (x: 
0.65 y: 0.36).  
 
Figure 1. Phosphatase inhibition assay A: with MC-LR-(5,6-
FAM) IC50 = 0.37 nM B: with MC-LR-(Alexa-430) IC50 = 0.61 nM 
 
With the desired derivatives in hand, we investigated if the 
prepared compounds retained the biological activity of the 
parent compound and therefore conducted a series of bioassays 
with the MC-LR derivatives. The inhibitory effect of labelled MC-
LR in comparison to unlabelled MC-LR was tested against 
protein phosphatase 2A. Initial tests showed that the 
fluorophores themselves were not interfering with the 
absorbance and the emission of the enzyme assay substrate, 
which allowed the use of compound 1 and 2 in the inhibition 
assays as test substrates (Figure 1). These derivatives were 
chosen to investigate if a negative charge in the compounds has 
a different influence on the inhibitory activity. For this purpose, 
the PP2A enzyme was incubated with different MCs derivatives 
in different concentrations (0.004 nM up to 40 nM) and 6,8-
difluoro-4-methylumbelliferyl phosphate (DiFMUP) as the 
substrate. The activity of the non-inhibited PP2A enzyme 
reaction is associated with the measured fluorescence of 
released 6,8-difluoro-4-methylumbelliferone. The data in Figure 
1 show that both MC-LR-(5,6-FAM) and MC-LR-(Alexa-430) 
inhibit PP2A with roughly equal IC50 values of 0.37 nM and 0.61 
nM, respectively. These measured values for the derivatives are 
one order of magnitude weaker in comparison with MC-LR, 
which displays an IC50 value of 0.05 nM.[33]  
 
Figure 2. Cell viability in Huh7 cells with MC-LR-(Alexa-430), EC50 = 16.3 µM 
To examine the cellular uptake and the toxicity of the MC-LR 
derivatives, MTT cytotoxicity assays for cell viability were 
performed. Huh7 cells were incubated with different 
concentrations of compound 2 for 24 h. Additionally, fluorescent 
imaging of the cells was performed after 4 h to visualize the 
uptake of the labelled toxin. In comparison to MC-LR (4.4 µM[15]) 
an EC50 value of 16.3 µM for compound 2 could be determined, 
although no complete cytotoxicity could be obtained (Figure 2).  
 
 
 
 
Figure 3. Fluorescent imaging of Huh 7 liver cells A: Fluorescent image of 
cells exposed to 100 µM MC-LR-(Alexa-430) B: Phase Contrast of cells 
exposed to 100 µM MC-LR-(Alexa-430)  C: Fluorescent image of cells 
exposed to 12.5 µM MC-LR-(Alexa-430) D: Phase Contrast of cells exposed to 
12.5 µM MC-LR-(Alexa-430) E: Fluorescent image at 100 µM with hydrolysed 
Alexa-430 F: Phase Contrast of cells exposed to 100 µM hydrolysed Alexa-430 
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In addition, visualization of the treated cells revealed that the 
compound could be detected in the cells (Figure 3). Uptake 
studies with the fluorophores alone did not reveal cellular uptake. 
Therefore, compound 2 demonstrated efficient cell uptake with 
retained cytotoxicity. 
We next analysed the toxicity of the modified compounds 1 and 
2 against aquatic organisms. The freshwater crustacean 
Thamnocephalus platyurus was chosen for the acute toxicity test, 
as this animal is a widely used for ecotoxicological studies.[37] 
Both compounds were administered over 24 h, and LC50 values 
of 5.7 µM for 1 and 15.7 μM for 2 could be determined. Again, 
these values are comparable to the parent toxin MC-LR (10.8 
μM)[33] (Figure 4).  
 
 
Figure 4. Acute toxicity assay A: with MC-LR-(5,6-FAM), LC50 = 5.7 µM B: 
with MC-LR-(Alexa-430), LC50 = 15.7 
Fluorescent imaging of animals treated with MC-LR-(Alexa-430) 
was revealed that the compound was only accumulated in the 
digestive track (Figure 5).[38]  
 
Figure 5. Fluorescent imaging of MC-LR-(Alexa-430) treated 
Thamnocephalus platyurus A: Fluorescent image at 100 µM with MC-LR-
(Alexa-430) B: Phase Contrast at 100 µM with MC-LR-(Alexa-430)   
Conclusion 
In conclusion, we have successfully developed a mild and 
operatively simple derivatization method for MC-LR in moderate 
to good yields. This method allows for the modification of the 
toxin with a variety of biologically important tags, such as 
fluorescent labels, diazirine and biotin tags. Furthermore, we 
demonstrated that the MC-LR derivative remains active towards 
one of the primary target, the enzyme protein phosphatase 2A 
(IC50 value of 0.37 nM) and is active towards aquatic organisms 
(LC50 value of 5.7 μM). In addition, the tagged MC-LR 
successfully undergoes cellular uptake by Huh 7 cells and 
retains toxicity (EC50 value of 16.3 versus 4.3 µM for MC-LR). 
Additional ongoing studies aim to investigate the uptake of the 
labelled MC-LR derivatives in various animals using these 
fluorescent probes.  
Experimental Section 
General  
The following reagents were purchased and used as received: NHS-
diazirine (Thermo Scientific), all reactive succinimidyl ester fluorophores 
(Invitrogen), Seaplaque agarose (Lonza), all further chemicals were 
purchased from Sigma-Aldrich Co. and were of analytical grade. 
Microcystin-LR was purchased from Enzo Life Sciences. 
Thamnocephalus platyurus for the acute toxicity assay was purchased 
from MicroBioTests Inc., Belgium. The protein phosphatase 2A enzyme 
was purchases from Promega, USA. 6,8-difluoro-4-methylumbelliferyl 
phosphate was received from Molecular Probes, Leiden, The 
Netherlands. HuH7 cells were originally provided by M. Heim, University 
Hospital Basel, Switzerland.  
For measuring the fluorescence in the protease inhibition assays a 
fluorescence microplate reader (Spectra MAX gemini XS; Molecular 
Devices Cooperation, Sunnyvale, California, USA) was used set at lem = 
365 nm, lex = 444 nm. All reactions were carried out in oven-dried 
glassware under an atmosphere of argon. HPLC purifications of the 
functionalized MC-LR was obtained on a Dionex P-680 HPLC System 
with a Phenomenex Gemini C18 5 μ (250 mm x 4.6 mm) column or a 
Phenomenex Gemini C18 5 μ (150 mm x 4.6 mm) column using a linear 
gradient: 5 % to 100 % CH3CN in 0.1 % Formic acid/H2O over 40 
minutes at a flow rate of 1 mL/min. For removal of the formic acid a final 
purification step was performed on a C18 SPE cartridge (500 mg, 
Supelco) starting with a first washing step with water to remove the acid 
and a final elution step with 80 % acetonitrile.  
The yield of modified MC-LR was determined using a NanoDrop 2000 
Spectrophotometer (Thermo scientific). UV-Vis data was recorded on an 
Agilent 8453 spectrophotometer, the fluorescence was measured on a 
Shimadzu 5301PC spectrofluorophotometer and the quantum yield was 
determined on a Hamamatsu absolute PL quantum yield spectrometer 
C11347 Quantaurus_QY. 1H-NMR spectra was recorded on a Bruker 
Avance III Ultrashield 600MHz with a 5 mm BBFO+ plus SP probe or a 
Bruker Avance III Ascend 700MHz with a 5 mm TCI (H-C/N-D) cryo 
probe spectrometers at room temperature. HRMS spectra were recorded 
on a Bruker maXis 4G instrument or measured by the mass 
spectrometric service of University of Bern on a Sciex QSTAR Pulsar 
mass spectrometer. HRMS spectra were obtained on a Bruker maXis 4G 
with ESI in positive or negative mode. MS-MS experiments were 
obtained on a Bruker Esquire 3000 with ESI in positive mode. 
Cell culturing, extraction and isolation 
M. aeruginosa UV-006 was cultivated in 500 mL Falcon tubes in mineral 
medium (200 mL) at 25 °C with 12h light and night cycle.[39] The resulting 
biomass was harvested every three months with a 6K15 centrifuge 
(Sigma), freezed and stored at -20 °C. To obtain pure MC-LR the 
cyanobacteria were suspended in 60 % acetonitrile (20 mL) per 1 g 
biomass and sonicated for 10 min (Branson 2510). The resulting 
homogenous mixture was centrifuged for 15 min at 25000 x g and the 
supernatants were combined and evaporated in a rotary evaporator 
(Büchi, Switzerland). The residue was dissolved in 60 % acetonitrile and 
prepurified on a C18 SPE cartridge (10 g, Supelco). The crude mixture 
was eluted with 80 % acetonitrile (500 mg biomass afforded 15 mg crude 
extract), concentrated and applied on a Dionex P-680 HPLC System with 
a Phenomenex Gemini-NX C18 5μ (75 mm x 21.2 mm) column using a 
linear gradient: 5 % to 100 % CH3CN in 0.1 % Formic acid/H2O over 
40 minutes at a flow rate of 5 mL/min for further purification. For removal 
of the formic acid a final purification step was performed on a C18 SPE 
cartridge (500 mg, Supelco) starting with a first washing step with water 
to remove the acid and a final elution step with 80 % acetonitrile. After 
removal of all volatiles and lyophilisation pure MC-LR (600 µg from 15 
mg crude extract) was afforded as a white solid. HPLC: tR = 18.1 min; MS 
(ESI): m/z = 995.9 [M+H]+ 
Synthesis of the modified MC-LR derivatives 
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General procedure for the functionalization MC-LR 
To a solution of MC-LR (1 eq.) in DMF (50 μL) were added Barton’s base 
(10 eq.) and the activated ester (1.5,1.1 or 4 eq.) in DMF (20 μL). The 
resulting mixture was stirred at 40 °C for 8h. All volatiles were removed 
under reduced pressure and the residue was purified by HPLC.  
MC-LR-(5,6-FAM), (1): 
According to the general procedure, compound 1 was synthesized 
starting from MC-LR (0.40 mg, 0.40 μmol). Barton’s base (0.70 mg, 4.09 
μmol) and 5(6)-carboxyfluorescein N-succinimidyl ester (0.22 mg, 0.46 
μmol) were used. Direct purification by HPLC afforded 1 (423 μg, 0.31 
μmol, 84 %) as a red solid. HPLC: tR = 23.6 min; HRMS-ESI: calcd. for 
C70H85N10O18+ [M+H]+: 1353.6038; found: 1353.6087. 
MC-LR-(Alexa-430), (2):  
According to the general procedure compound 2 was synthesized 
starting from MC-LR (1.00 mg, 1.00 μmol). Barton’s base (1.10 mg, 6.43 
μmol) and Alexa 430 succinimidyl ester (0.78 mg, 1.11 μmol) were used. 
Direct purification by HPLC afforded 2 (1.36 mg, 0.92 μmol, 74 %) as a 
red solid. HPLC: tR = 33.4 min; HRMS-ESI: calcd. for C71H95N11O18F3S- 
[M-H]-: 1478.6524; found: 1478.6527. 
MC-LR-(Alexa-488), (3):  
According to the general procedure compound 3 was synthesized 
starting from MC-LR (0.20 mg, 0.20 μmol). Barton’s base (0.34 mg, 2.0 
μmol) and Alexa 488 5-sulfodichlorphenol ester (0.25 mg, 0.30 μmol) 
were used. Direct purification by HPLC afforded 3 (0.17 mg, 0.11 μmol, 
55 %) as a red solid. HPLC: tR = 10.9 min; HRMS-ESI: calcd. for 
C70H84N12O22S22- [M-H-H]2-: 754.2638; found: 754.2625. 
MC-LR-(Texas-Red), (4):  
According to the general procedure compound 4 was synthesized 
starting from MC-LR (0.50 mg, 0.50 μmol). Barton’s base (0.86 mg, 5.02 
μmol) and Texas Red succinimidyl ester (0.50 mg, 0.61 μmol) were used. 
Direct purification by HPLC afforded 4 (650 μg, 0.38 μmol, 76 %) as a 
red solid. HPLC: tR1 = 23.6 min; tR2 = 25.6 min; HRMS-ESI: calcd. for 
C86H114N13O19S2Na2+ [M+H+Na]2+: 859.8841; found: 859.8852. 
Phosphatase inhibition assays 
The enzyme mixture was prepared as followed: PP2A enzyme (2 μL) 
was dissolved in EGTA (650 μL, 1 mM), DTT (50 μL, 10 mM in 5 mM 
sodium acetate pH = 5.2), MnCl2 (200 μL, 6 mM) and BSA (100 μL, 5 
mg/mL). The reaction buffer was prepared out of MnCl2 (290 μL, 6 mM), 
MgCl2 (290 μL, 0.8 M) and BSA (290 μL, 5 mg/mL). In a 200 μL well plate 
25 μL of the enzyme mixture was used. To achieve a final concentration 
of 25 mU PP2A (200 μL), Tris-HCl (30 μL, 50 mM, pH = 7.0) and the 
reaction buffer (15 μL) were added. The mixture was incubated for 10 
minutes at 37 °C. Afterwards 10 μL of 1 and 2 were added in various 
concentrations (0.004 nM up to 40 nM). Only the fluorophores were used 
as control experiment to test possible interference with the experimental 
setup. Subsequent incubation at 37 °C for 10 minutes was followed. To 
start the measurement 6,8-difluoro-4-methylumbelliferyl phosphate (120 
μL, 10 mM dissolved in 50 mM Tris-HCl pH = 7.0) solution was added. 
After a final incubation over 5 minutes at 37 °C the fluorescence 
measurement was started by taking a data point every 30 seconds for 45 
minutes. To obtain the activity of the phosphatase, linear regression was 
used using Graph Pad Prism 4.1 for Windows.  
MTT assay for cytotoxicity 
Human hepatoma cells (Huh7) cells were plated after growing in DMEM 
containing GlutaMAX (LuBioSciene) with 10 % FBS in a humidified 
incubator (5 % CO2, 37 °C), in a 96-well plate at a density of 50000 cells 
per condition in 50 μL fractions. After 24 h of incubation, a series of 
diluted solution of compound 2 in medium without FBS was added to the 
cells. After additional 24 h, the mixture was replaced with fresh medium 
(200 μL). Pictures of the uptake into the cells were taken with an 
Olympus CKX41 biological microscope with a 10x objective. Analysis of 
the pictures were performed with Cell B Version 3.2. Afterwards MTT (20 
μL, 5 mg/mL) was added, followed by an incubation over 2 h at 37 °C. 
Subsequently, the solution was removed and DMSO (200 μL) was added 
and mixture was shaken for 15 min. Soerensen buffer (25 µL) was added 
and absorbance was measured at 570 nm on a plate reader.  
Acute toxicity assay 
To determine the acute toxicity of the modified MC-LR, compound 1 and 
2 was utilized in an acute toxicity assay with Thamnocephalus platyurus 
in a multiwell plate using instar II-III larvae hatched from cysts during 24 
hours. Compounds 1 and 2 were tested in various concentrations (0.5 to 
100 μM) using 30 animals per condition. The LC50 value was calculated 
using the nonlinear regression Graph Pad Prism 4.1 for Windows was 
used. 
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